Blood-Stained Mucus in an Elderly Patient

Clinical Scenario

Charles King, 71, books a video consultation about blood when clearing his throat. He has been noticing dark blood-streaked mucus 3-4 times weekly for 2-3 months, mainly in the morning. He has also lost 6-7kg over 5-6 months without trying. He has a 40-pack-year smoking history, COPD, atrial fibrillation (on rivaroxaban), type 2 diabetes, and hypertension. He initially attributed the blood to his anticoagulant but is now worried. He also reports a hoarse voice for the past few weeks.

What This Case Tests

Differentiating haemoptysis (coughing up blood) from post-nasal bleeding (blood from the nasopharynx); recognising the combination of blood-streaked mucus, weight loss, hoarseness, and heavy smoking history as a red flag constellation; considering both lung cancer and nasopharyngeal or laryngeal malignancy; not attributing the bleeding to rivaroxaban without excluding malignancy; arranging urgent investigation.

Common Mistakes Trainees Make

The three most common mistakes are: attributing the blood to rivaroxaban without further investigation (anticoagulants can unmask bleeding from an underlying lesion but do not cause it de novo — the blood must have a source), not recognising the sinister combination of blood, weight loss, and hoarseness in a heavy smoker (this is a red flag constellation requiring urgent investigation), and not distinguishing between haemoptysis and post-nasal bleeding (the blood is noticed when clearing the throat, suggesting a nasopharyngeal or laryngeal source rather than a pulmonary source).

The Consultation Challenge

Charles has a constellation of symptoms that, together, are alarming: blood-streaked mucus for 2-3 months, unintentional weight loss of 6-7kg, hoarseness, a 40-pack-year smoking history, and age 71. Any one of these in isolation might be benign. Together, they require urgent investigation for malignancy.

The first clinical question is the source of the blood. Charles notices blood when clearing his throat, not when coughing. This suggests the blood may originate from the nasopharynx or larynx rather than the lungs. The hoarseness supports a laryngeal or nasopharyngeal process. However, pulmonary pathology cannot be excluded without imaging.

Do not accept the rivaroxaban explanation. Charles initially attributed the blood to his anticoagulant, and this is a logical assumption that many patients (and some clinicians) make. However, anticoagulants do not cause bleeding from nowhere — they may exacerbate bleeding from an existing lesion. The blood has a source, and that source needs identifying. "I understand why you might think the blood thinner is causing this, but actually, blood thinners do not create bleeding on their own — they can make existing bleeding worse. That means we need to find where the blood is coming from."

The weight loss is the most concerning feature. Unintentional weight loss of 6-7kg over 5-6 months in a 71-year-old with a heavy smoking history is a cancer red flag regardless of the other symptoms. Combined with blood and hoarseness, urgent investigation is mandatory.

Management: urgent 2-week wait referral. The question is which pathway — lung cancer (chest X-ray and CT) or head and neck (ENT assessment with nasendoscopy). Given the combination of possible post-nasal blood source, hoarseness, AND smoking history with possible pulmonary involvement, both pathways may be needed. Start with a chest X-ray (can be arranged today) and an urgent ENT referral for nasendoscopy. If the chest X-ray is abnormal, add the lung cancer pathway.

Arrange bloods: FBC (anaemia from chronic blood loss), inflammatory markers, renal function, liver function, and coagulation (check rivaroxaban is not supratherapeutic). Check his rivaroxaban compliance and dose.

Time check: Spend the first 4 minutes on symptom history and source differentiation. By minute 6, identify the red flag constellation and explain the urgency. Arrange investigations and referral between minutes 7-10. Use the remaining time for safety netting and emotional support.

How Examiners Mark This Case

Data Gathering and Diagnosis: Examiners assess whether you differentiate the source of blood (nasopharyngeal versus pulmonary), identify the full constellation of concerning features (blood, weight loss, hoarseness, smoking history, age), screen for additional red flags (dysphagia, lymphadenopathy, bone pain), and do not accept the rivaroxaban explanation without investigation. The history should reveal clinical reasoning — connecting the dots between individual symptoms.

Clinical Management and Medical Complexity: Examiners expect urgent investigation via the suspected cancer pathway. They look for whether you arrange both a chest X-ray (for pulmonary assessment) and an ENT referral (for nasopharyngeal and laryngeal assessment given the hoarseness and post-nasal blood source). Checking rivaroxaban compliance and dose demonstrates thorough management. A trainee who attributes the bleeding to rivaroxaban and does not investigate further will score very poorly.

Relating to Others: Examiners assess whether you explain the urgency honestly without causing panic, address Charles's initial rivaroxaban self-explanation compassionately, and provide emotional support for what is a frightening combination of symptoms. Charles should understand why you are concerned and what will happen next.

Example Opening

Strong opening: "Hello Charles, thank you for coming in about the blood you have been noticing. I want to take this seriously and make sure we work out where it is coming from. Can you describe exactly what happens — is it when you cough, or when you clear your throat?"

When addressing the rivaroxaban explanation: "I can see why you might think the blood thinner is causing this, and that is a logical thought. But here is the thing — blood thinners do not create bleeding from nowhere. If there is blood, there is a source, and we need to find it. Combined with the weight you have lost and the change in your voice, I want to get this investigated urgently."

When explaining the urgency: "I do not want to alarm you, but I want to be straight with you. The combination of blood, weight loss, and voice change in someone with your smoking history is something we need to check urgently. I am going to arrange a chest X-ray and a specialist appointment so we can find out exactly what is going on."

Avoid: "It is probably just the rivaroxaban causing some irritation." (Dangerous false reassurance that would delay cancer investigation).

How This Appears in the SCA

This case tests pattern recognition — the ability to see individual symptoms as part of a concerning constellation rather than managing each in isolation. The rivaroxaban red herring tests whether you can think critically about a patient's self-explanation. Examiners assess whether you recognise the cancer risk and arrange appropriate urgent investigation.

Key Statistic

Unexplained weight loss of more than 5% body weight over 6-12 months is a recognised cancer red flag. Laryngeal cancer accounts for approximately 2,000 new cases annually in the UK, with smoking and alcohol as the primary risk factors. Hoarseness lasting more than 3 weeks in a smoker warrants urgent ENT assessment per NICE NG12.

Relevant Guidelines

• NICE NG12: Suspected cancer — recognition and referral
• NICE NG122: Lung cancer — diagnosis and management
• NICE guideline on head and neck cancers
• NICE CG144: Venous thromboembolic diseases — anticoagulation management.

Frequently Asked Questions

How do I differentiate haemoptysis from post-nasal bleeding?

Haemoptysis (pulmonary source): blood is coughed up, often mixed with sputum, may be frothy, and is associated with respiratory symptoms. Post-nasal bleeding (nasopharyngeal source): blood is noticed when clearing the throat or hawking, may drip down the back of the throat, and is associated with nasal or throat symptoms. The distinction matters because it guides the investigation pathway — pulmonary source requires chest imaging, nasopharyngeal source requires ENT assessment. In Charles's case, the post-nasal pattern with hoarseness suggests a head and neck source, but chest imaging is still needed given his smoking history.

Can anticoagulants cause bleeding without an underlying lesion?

No — anticoagulants exacerbate bleeding from existing lesions or vascular abnormalities, but they do not create de novo bleeding from healthy tissue. If a patient on anticoagulation develops new bleeding, the anticoagulant may be making an existing problem more visible, but there is always a source that needs identifying. This is a critical clinical principle — never attribute new bleeding solely to anticoagulation without investigating the cause.

What investigation pathway should I use when the source of bleeding is unclear?

When the clinical picture could represent pulmonary or upper aerodigestive tract pathology, investigate both. Arrange a chest X-ray (rapid, can be done same day, screens for pulmonary mass), and refer urgently to ENT for nasendoscopy (direct visualisation of the nasopharynx and larynx). If the chest X-ray shows a suspicious lesion, add the lung cancer 2WW pathway. If the nasendoscopy identifies a lesion, the ENT team will manage. Do not wait for one result before initiating the other pathway.

What is the significance of hoarseness in a smoker?

NICE NG12 recommends urgent 2WW ENT referral for any person with unexplained hoarseness lasting more than 3 weeks. In a smoker, hoarseness may indicate laryngeal cancer, recurrent laryngeal nerve palsy from a lung apex tumour (Pancoast), or vocal cord dysfunction. Combined with blood-streaked mucus and weight loss, it significantly raises the pre-test probability of malignancy. Hoarseness in isolation may be benign (laryngitis, voice strain), but in this clinical context it is a red flag.

What blood tests should I arrange alongside the referral?

FBC (anaemia from chronic blood loss, raised white cells suggesting infection, thrombocytopenia suggesting marrow pathology), CRP/ESR (inflammatory markers), U&Es and LFTs (baseline for staging and treatment planning), calcium (hypercalcaemia as a paraneoplastic feature of lung cancer), coagulation studies (check rivaroxaban is not supratherapeutic), and HbA1c (diabetes monitoring). These provide baseline information for the specialist and may identify additional pathology.